Atezolizumab real-world population PK
A two-compartment population PK model representing atezolizumab concentration and exposure with body weight, albumin, sex, and anti-therapeutic-antibody covariates.
- Therapeutic
- Atezolizumab
- Target
- PD-L1 / CD274
- Disease
- Non-small cell lung cancer
Biological model
A two-compartment population PK model representing atezolizumab concentration and exposure with body weight, albumin, sex, and anti-therapeutic-antibody covariates.
Intervention
Atezolizumab
Biological focus
PD-L1 / CD274
Context
Non-small cell lung cancer
Model details
A two-compartment population PK model representing atezolizumab concentration and exposure with body weight, albumin, sex, and anti-therapeutic-antibody covariates.
Modeled states
- AUCug*day/mL
Modeled dynamic state for auc.
- A centralmg
Modeled dynamic state for a central.
- A peripheralmg
Modeled dynamic state for a peripheral.
Key readouts
- Central atezolizumab concentrationunknown
Model-derived readout for central atezolizumab concentration.
- Peripheral atezolizumab concentrationunknown
Model-derived readout for peripheral atezolizumab concentration.
- Cumulative atezolizumab exposureunknown
Model-derived readout for cumulative atezolizumab exposure.
- AUCug*day/mL
Model-derived readout for auc.
- A centralmg
Model-derived readout for a central.
Explore this model
Choose a starting point to view its result. Adjust key model inputs when you want to explore a different outcome.
Article median
How do real-world patient covariates change atezolizumab concentration and exposure? Explore this intervention regimen through Central atezolizumab concentration, Peripheral atezolizumab concentration, Cumulative atezolizumab exposure. This is a mechanistic product exploration, not a paper-result reproduction.
Questions to explore
- How do real-world patient covariates change atezolizumab concentration and exposure?
Starting result
This result reflects the starting settings. Run your changes to update it.
Model inputs
Five scientist-facing controls at most.
Compare a parameter
How does one model input change the response?
How do real-world patient covariates change atezolizumab concentration and exposure?
CL pop L day
Model parameter controlling cl pop l day.
Exploratory range around the default value.
5 evenly spaced values in L/day. Other model inputs and the simulation window stay fixed.
Interpret with care
- Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.
- Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario.
Review the server-confirmed fixed price before starting the comparison.
Comparative response
End-of-window response across the selected parameter values.
Choose an exploratory range around the default, review the fixed price, and run the comparison.
Scientific reference
Supporting publication
Real-World Pharmacokinetics, Effectiveness, and Safety of Atezolizumab in Patients With Unresectable Advanced or Recurrent NSCLC: An Exploratory Study of J-TAILJTO Clinical and Research Reports
